FDA to Sharply Restrict Use of Two Monoclonal Antibody Treatments
The Food and Drug Administration (FDA) will sharply restrict the use of two monoclonal antibody treatments according to a new report by the Washington Post.
According to WaPo, the Biden Administration is expected to halt distribution of monoclonal antibody treatments made by Regeneron Pharmaceuticals and Eli Lilly because they are ‘ineffective against Omicron.’
The Washington Post reported:
The Food and Drug Administration is poised as soon as Monday to restrict two monoclonal antibodies, saying the covid-19 treatments should not be employed in any states because they are ineffective against the dominant omicron variant, according to two senior administration health officials.
As a result, the Biden administration will pause distribution of the therapies,
